Incyte is trading lower this morning, reflecting mild pressure that aligns with a broader downturn in the healthcare sector, including a 1.1% decline in peer AbbVie.
The stock's recent focus has been dominated by the FDA approval of Atebrioz for the treatment of fibrodysplasia ossificans progressiva, a milestone that triggers a 25 million dollar payment to Incyte and grants the company a Rare Pediatric Disease Priority Review Voucher. While this regulatory win has generated positiv